Caerulomycin A
Based on 3 publication(s) in Google Scholar
Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 21802-37-9
- Formule: C12H11N3O2
- Masse moléculaire:229.24
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
Antifungal Compound Library
HY-L048
-
Antibacterial Compound Library
HY-L049
-
Antibiotics Library
HY-L067
-
Microbial Metabolite Library
HY-L084
-
Transcription Factor-Targeted Library
HY-L090
-
Osteogenesis Compound Library
HY-L131
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Bacteria-Sourced Compound Library
HY-L254
Publications Citing Use of MedChemExpress (MCE) Caerulomycin A
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.26 μM
Compound: 7
|
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 21770434] |
| HL-60 | IC50 |
0.71 μM
Compound: 7
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 21770434] |
| K562 | IC50 |
>50 μM
Compound: 7
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 21770434] |
| KB | IC50 |
>50 μM
Compound: 7
|
Cytotoxicity against human KB cells after 72 hrs by MTT assay
Cytotoxicity against human KB cells after 72 hrs by MTT assay
|
[PMID: 21770434] |
Caerulomycin A (0-0.31 μM; 5 days, 72 h) dose-dependently induces CD4+Foxp3+ Treg generation in non-polarizing conditions, synergistically enhances TGF-β-mediated Treg generation, suppresses Th1 and Th17 cell differentiation and cytokine secretion, reduces CD44 expression, and increases mitochondrial membrane potential in mouse naïve CD4+ T cells[1].
Caerulomycin A (0.04-0.15 μM; 48 h, 4 days) dose-dependently suppresses CD4+ effector T cell activation and alloreactive T cell proliferation in mouse cell cultures via generated Tregs (with or without TGF-β)[1].
Caerulomycin A (0.04-0.31 μM; 24 h pre-incubation) dose-dependently suppresses IFN-γ/IL-6-mediated STAT1 signaling by enhancing SOCS1 expression, reduces STAT1 target gene and protein expression, and enhances TGF-β-mediated Smad3 signaling in mouse CD4+ T cells[1].
Caerulomycin A (0.04-0.15 μM; 5 days) dose-dependently rescues mouse CD4+Foxp3+ Treg generation from IFN-γ-mediated suppression, and this Treg generation is strictly dependent on Smad3 activity[1].
Caerulomycin A (0.08-0.31 μM; 6 days) inhibits IL-4 expression in terminally differentiated mouse Th2 CD4+ T cells, with a concentration-dependent reduction in IL-4+ cell percentage over 6 days[2].
Caerulomycin A (0.08-0.31 μM; 6 days) concentration-dependently inhibits the differentiation of mouse naïve CD4+ T cells to Th2 cells, reducing both IL-4 expression (with significant inhibition at 0.31 μM) and GATA-3 expression in IL-4+ CD4+ T cells after 6 days of culture[2].
Caerulomycin A (5-100 μg/mL; up to 96 h) inhibits growth of diverse yeasts, filamentous fungi, uredospores, and bacteria in an agar dilution assay, with complete inhibition ranging from 5 μg/mL (for Candida albicans, Saccharomyces cerevisiae, Isaria cretacea, Rhizopus nigricans at 24 h) to 100 μg/mL (for Escherichia coli and Puccinia graminis var. tritici race 15B uredospore germination at all time points) when incubated at 28°C for up to 96 hours[3].
Caerulomycin A (50 μg/mL; 7-day fermentation) inhibits growth of Candida albicans in a disc diffusion assay, produced via a 7-day fermentation of Streptomyces caeruleus PRL 1687 in starch-Czapelt medium[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Caerulomycin A (1-10 mg/kg; p.o.; daily; 12 days) dose-dependently attenuates asthma symptoms in OVA-induced BALB/c mice, with the 10 mg/kg oral daily dose achieving significant suppression of lung inflammation, eosinophil infiltration, Th2 cytokine production, and IgE levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DBA/1 (male, 6-8 weeks of age, collagen-induced arthritis model)[1]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:daily; 50 days
-
Result:Reduced arthritis clinical severity scores in a dose-dependent manner.
Showed significantly reduced inflammatory response and bone degeneration, with the 10 mg/kg dose showing the greatest reduction.
Significantly decreased knee joint proinflammatory cytokine levels (IFN-γ, TNF-α, IL-6).
Increased percentage of Tregs in draining lymph nodes, with the 10 mg/kg group reaching 13% CD4+Foxp3+ cells.
Significantly reduced IFN-γ and TNF-α secretion in in vitro restimulated lymph node cells with bovine collagen type II.
Significantly lowered serum levels of MMP-3.
-
Animal Model:BALB/c (female, 6-8 weeks old, OVA-induced asthma model)[2]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 12 days (days 13-24)
-
Result:Significantly reduced lung inflammation.
Reduced IL-5 and IL-13 levels in BAL fluid from.
Significantly reduced total IgE levels in BAL fluid.
Significantly reduced lung inflammation.
Significantly reduced total BAL fluid cell counts.
Chemical Information
-
CAS No. 21802-37-9
-
Appearance Solid
-
Masse moléculaire 229.24
-
Formule C12H11N3O2
-
Color White to off-white
-
SMILES
COC1=CC(C2=NC=CC=C2)=NC(/C=N/O)=C1
-
Synonyms
Cerulomycin; Caerulomycin
-
Initial Source
Streptomyces caeruleus
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
Transient mechanical activation of the Piezo1 channel facilitates ex vivo expansion of hematopoietic stem cells. [Abstract]2026 Jan 9. PMID: 41507440 -
J Ovarian Res
IFN-γ in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis. [Abstract]2023 Nov 25;16(1):229. PMID: 38007483 -
Eur J Med Res
Efficacy of caerulomycin A in modulating macrophage polarization and cytokine response in a murine model of lipopolysaccharide-induced sepsis. [Abstract]2025 Jan 10;30(1):22. PMID: 39794821
Solvant et solubilité
DMSO : 150 mg/mL (654.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Gurram RK, et al. Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs). J Biol Chem. 2014;289(25):17515-17528. [Content Brief]
[2]. Kujur W, et al. Caerulomycin A inhibits Th2 cell activity: a possible role in the management of asthma. Sci Rep. 2015;5:15396. Published 2015 Oct 20. [Content Brief]
[3]. FUNK A, et al. Caerulomycin, a new antibiotic from Streptomyces caeruleus Baldacci. I. Production, isolation, assay, and biological properties. Can J Microbiol. 1959 Aug;5:317-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3622 mL | 21.8112 mL | 43.6224 mL | 109.0560 mL |
| 5 mM | 0.8724 mL | 4.3622 mL | 8.7245 mL | 21.8112 mL | |
| 10 mM | 0.4362 mL | 2.1811 mL | 4.3622 mL | 10.9056 mL | |
| 15 mM | 0.2908 mL | 1.4541 mL | 2.9082 mL | 7.2704 mL | |
| 20 mM | 0.2181 mL | 1.0906 mL | 2.1811 mL | 5.4528 mL | |
| 25 mM | 0.1745 mL | 0.8724 mL | 1.7449 mL | 4.3622 mL | |
| 30 mM | 0.1454 mL | 0.7270 mL | 1.4541 mL | 3.6352 mL | |
| 40 mM | 0.1091 mL | 0.5453 mL | 1.0906 mL | 2.7264 mL | |
| 50 mM | 0.0872 mL | 0.4362 mL | 0.8724 mL | 2.1811 mL | |
| 60 mM | 0.0727 mL | 0.3635 mL | 0.7270 mL | 1.8176 mL | |
| 80 mM | 0.0545 mL | 0.2726 mL | 0.5453 mL | 1.3632 mL | |
| 100 mM | 0.0436 mL | 0.2181 mL | 0.4362 mL | 1.0906 mL |
Caerulomycin A Related Classifications
HY-114495 Related Classifications
Powered by Bioz